Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Chubb
Boehringer Ingelheim
Teva
Dow
Fuji
Moodys
Farmers Insurance
Covington

Generated: May 21, 2018

DrugPatentWatch Database Preview

CO-GESIC Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Co-gesic patents expire, and when can generic versions of Co-gesic launch?

Co-gesic is a drug marketed by Cent Pharms and Ucb Inc and is included in two NDAs.

The generic ingredient in CO-GESIC is acetaminophen; hydrocodone bitartrate. There are sixty-six drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the acetaminophen; hydrocodone bitartrate profile page.
Summary for CO-GESIC
US Patents:0
Applicants:2
NDAs:2
Bulk Api Vendors: 115
Formulation / Manufacturing:see details
DailyMed Link:CO-GESIC at DailyMed
Drug patent expirations by year for CO-GESIC

US Patents and Regulatory Information for CO-GESIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cent Pharms CO-GESIC acetaminophen; hydrocodone bitartrate CAPSULE;ORAL 089360-001 Mar 2, 1988 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ucb Inc CO-GESIC acetaminophen; hydrocodone bitartrate TABLET;ORAL 087757-001 May 3, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
Healthtrust
Daiichi Sankyo
Deloitte
Citi
McKinsey
Harvard Business School
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.